Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

A simple urine test can more than halve the number of cystoscopies necessary to follow up high-risk bladder cancer patients, new research has found. Cystoscopies involve inserting a flexible probe ...

A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...

A new urine test could spare bladder cancer survivors from a painful follow-up procedure needed to ensure their cancer hasn't come back, researchers report. People who've gotten surgery for high-risk ...

In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...

Receiving a diagnosis of stage 1 urothelial carcinoma (bladder cancer) can feel overwhelming, but at this stage, the cancer ...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc., a leader in endoscopy and related technology solutions, announced its system for performing Blue Light Cystoscopy with Cysview® ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Cystoscopy remains an essential diagnostic procedure in urology, yet it is frequently associated with discomfort and pain that may compromise patient compliance and overall procedural experience.

Please provide your email address to receive an email when new articles are posted on . Cystoscopies for recurrent UTIs yield little clinical benefit for patients both with and without high-risk ...

This transcript has been edited for clarity. Cheryl Lee, MD: Welcome to Medscape InDiscussion. I'm Dr Cheryl Lee. Today we'll be discussing non–muscle-invasive bladder cancer. How should we approach ...